# Cogent Biosciences Inc. (COGT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $34.76, market value $6.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Cogent Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 766.3×**. Each dollar of revenue is priced at 766.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 12.8×**. The shares trade at 12.8× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -5.1%** (5-yr avg -20.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -51.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -11.9%**. Return on all capital, debt included, is -11.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -8.0%**. Each dollar of assets produces -8.0% of profit.

## Growth
- **EPS growth (1 yr): -11.3%**. Earnings per share fell 11.3%.

## Financial health
- **Debt to equity: 0.35**. Debt is 0.35 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.1×**. It would take 1.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Cogent Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Cogent Biosciences Inc.; the consensus is strong_buy, with an average price target of $55.82 (+61% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 168.6%** (YTD -2.1%, 3-mo 12.1%). The shares are up 168.6% over twelve months including dividends.
- **From 52-week high: -20.5%** (199.7% above the low). Trading 21% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 2.44** (volatility 128%). Beta of 2.44 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=COGT · Page: https://foliofundamentals.com/stocks/cogt

Not investment advice.